Victoria Cornelius is Senior Lecturer in Medical Statistics and Clinical Trials at Imperial College London, Deputy Head of Statistics in Imperial Clinical Trials Unit (ICTU), and Joint Academic Lead for the Research Design Service (RDS) for West London.
Victoria research is in trials of drug and surgical interventions with experience across a broad range of therapeutic areas including respiratory, allergy, cancer and mental health. She leads the cancer and surgical statistical portfolio for ICTU. Her statistical research is in the use of time-to-event signal detection methods to identify adverse drug reactions and the selection and presentation of harm information in clinical trials. Her collaborative research includes both early and later phase clinical trials and she has experience in pharmacoepidemiology and network meta-analysis. Victoria established the NIHR Statistics Group in 2011 with the support of NOCRI which she subsequently co-led until March 2017. The Group supports early career statisticians through training and networking to share best practice and provides opportunity for applied statisticians, clinicians and scientists to collaborate on research projects. Her work with the Group included being part of and leading national collaborative projects in laboratory and early phase clinical trials research to support the translation of statistical methods into practice. She is the statistical supervisor for two doctoral and two post-doctoral Fellows undertaking clinical trials, and supervisor for PhD in prediction modelling for post-cancer treatment anxiety. Victoria is a statistical editor for Thorax and panel member of the NIHR Clinical Trials fellowship board.
Victoria obtained a BSc in Mathematics from Cardiff University in 1997 and competed a PhD in Statistics in 2000 before joining the Centre for Statistics in Medicine in Oxford working in cancer research. In 2005 she moved to the Drug Safety Research Unit where she designed and analysed post-marketing surveillance studies to monitor the safety of medicines newly released to market. In 2009 she joined Respiratory Biomedical Research Unit (BRU) at Southampton University Hospitals NHS Trust as a NIHR senior statistician working on allergy and respiratory translational research projects. In 2011 she joined King’s College London as a Senior Lecturer in Medical Statistics where she subsequently became the Deputy Director for Research Design Service London, and affiliated statistical lead for King’s Clinical Trials Unit before joining Imperial College in February 2016.
et al., Can the question-behaviour effect enhance uptake of cardiovascular health checks in primary care?, European Health Psychologist
et al., 2017, Online versus face-to-face pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: randomised controlled trial., Bmj Open, Vol:7
et al., 2017, Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT): the role of anti-IgE in severe paediatric eczema: study protocol for a randomised controlled trial, Trials, Vol:18, ISSN:1745-6215
et al., 2017, The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan, Trials, Vol:18, ISSN:1745-6215
et al., 2017, Potential health impact and cost-effectiveness of drug therapy for prehypertension., Int J Cardiol, Vol:240, Pages:403-408